Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated ...

In the multivariate analysis, the HR for death for the FOLFOXIRI plus bevacizumab group compared with the FOLFIRI plus bevacizumab group was 0·77 (95% CI 0·61–0·96; p=0·02; appendix); ECOG performance ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The survival benefit with cadonilimab in cervical cancer in the overall phase 3 COMPASSION-16 study population was sustained ...

The most common TRAEs of any grade were acneiform rash (93%), diarrhea (89%), proteinuria (78%), and dry skin (64%).

Discover a study that demonstrated that a combination of toripalimab and bevacizumab significantly improves survival outcomes ...

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA™, would be the first ...

First-line treatment with alectinib and bevacizumab appears to be effective for patients with ALK-rearranged, metastatic NSCLC, according to researchers.

To evaluate long-term outcomes of anti-VEGF therapy for neovascular age-related macular degeneration (nAMD) in the Netherlands (NL), where bevacizumab is the mandated first-line drug, compared to high ...

BackgroundThe monoclonal antibody bevacizumab effectively inhibits angiogenesis in several types of cancers by blocking vascular endothelial growth factor. However, life‐threatening cardiovascular ...